Eppin Pharma Awarded a Small Business Research Loan for $250,000 from the NCBC

Eppin Pharma of Chapel Hill is pleased to announce that it was one of two companies to receive a Small Business Research Loan for $250,000 from the North Carolina Biotech Center to advance the development of its orally delivered, safe, reversible, non-hormonal male contraceptive. Funds will be utilized to optimize bioavailability and assess the safety and efficacy of the company’s lead compounds in preparation for an IND application anticipated in 2017/2018.

July 21, 2016
Read more at http://wraltechwire.com/nc-biotech-center-awarded-2-5m-to-universities-and-companies/15866728/?utm_medium=email&utm_campaign=newsletter&utm_source=wraltechwire#2Ty3POvRpWR4HcQD.99

About Eppin Pharma

Eppin Pharma Inc. of Chapel Hill, North Carolina, is an emerging pharmaceutical company focused on developing a safe, non-hormonal male contraceptive taken orally. The company was founded based upon technology licensed from the University of North Carolina at Chapel Hill and has received support from the University of North Carolina at Chapel Hill’s Carolina KickStart Commercialization program (North Carolina Translational and Clinical Sciences Institute).

 Research support referred to in this press release will be supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number R41HD084007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts


Eppin Pharma Inc                         www.eppinpharma.com

 Zahed Subhan PhD, CEO                  zsubhan@eppin.com

 Michael O’Rand PhD, President      morand@eppin.com

Jeffrey Handler PhD, COO               jhandler@eppin.com

Eppin Pharma Awarded STTR Grant from NIH to Evaluate Novel Targeted Male Contraceptive “Pill” in Primates

Chapel Hill, NC–(BUSINESS WIRE)—Eppin Pharma Inc. announced today that it has been awarded a Small Business Technology Transfer (STTR, phase 1) grant from the National Institutes of Health (NIH) to evaluate the effectiveness of its lead contraceptive candidate, EP007 in primates. EP007 is currently being developed as a potential non-hormonal birth control pill to be used by men as a revolutionary alternative to currently available family planning options.

The compound, a small organic molecule, targets EPPIN, a protein only present in the male on sperm in the testis and epididymis. By selectively binding EPPIN, the compound is able to inhibit sperm motility.

“The localization of EPPIN and the selective binding to EPPIN by EP007, offers the potential for effective contraception with minimal or no side effects,” commented Michael O’Rand PhD, President, Eppin Pharma Inc.

Building upon previous research conducted at the University of North Carolina, Chapel Hill, the STTR funded study will confirm EP007’s mechanism of action and offer “proof of principle” that Eppin Pharma’s lead candidate is available in semen in primates, providing convincing evidence that this method of contraception is feasible for use by men.

“We envision that our contraceptive will be administered orally and be taken on-demand a relatively short time before sexual activity. Little has changed in the field of contraception in more than 50 years since the introduction of the birth control pill. Eppin Pharma’s approach is truly pioneering and offers a solution to an unmet need in family planning” said Zahed Subhan PhD, CEO.

“An award from this highly competitive STTR program is a testimony to the importance and potential breakthrough opportunity associated with a novel form of contraception that does not disrupt hormonal systems” said Zahed Subhan, CEO of Eppin Pharma Inc. “We are deeply appreciative of the assistance provided by the NIH STTR program.”

About Eppin Pharma

Eppin Pharma Inc. of Chapel Hill, North Carolina, is an emerging pharmaceutical company focused on developing a safe, non-hormonal male contraceptive taken orally. The company was founded based upon technology licensed from the University of North Carolina at Chapel Hill and has received support from the University of North Carolina at Chapel Hill’s Carolina KickStart Commercialization program (North Carolina Translational and Clinical Sciences Institute).

 Research support referred to in this press release will be supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number R41HD084007. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts


Eppin Pharma Inc                         www.eppinpharma.com

 Zahed Subhan PhD, CEO                  zsubhan@eppin.com

 Michael O’Rand PhD, President      morand@eppin.com

 Jeffrey Handler PhD, COO               jhandler@eppi

Pharmacol Ther. 2015 Nov 22.

Non-hormonal male contraception: A review and development of an Eppin based contraceptive.

O’Rand MG, Silva EJ, Hamil KG

Abstract

Developing a non-hormonal male contraceptive requires identifying and characterizing an appropriate target and demonstrating its essential role in reproduction. Here we review the development of male contraceptive targets and the current therapeutic agents under consideration. In addition, the development of EPPIN as a target for contraception is reviewed. EPPIN is a well characterized surface protein on human spermatozoa that has an essential function in primate reproduction. EPPIN is discussed as an example of target development, testing in non-human primates, and the search for small organic compounds that mimic contraceptive antibodies; binding EPPIN and blocking sperm motility. Although many hurdles remain before the success of a non-hormonal male contraceptive, continued persistence should yield a marketable product.

Copyright © 2015 Elsevier Inc. All rights reserved.

KEYWORDS:

EPPIN; Male contraception; Reproductive pharmacology; Semenogelin; Sperm

PMID:    26593445          [PubMed – as supplied by publisher]